This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .
Treatment of angina pectoris with dipyridamole: a double-blind study.
: In a double-blind study , 48 patients ( age range , 47 to 75 ) with angina pectoris received either dipyridamole ( Persantine ) ( 200 mg daily ) or placebo for an average of five months . Nitroglycerin was taken sublingually as required for relief of acute attacks . Previous use of long-acting nitrates had produced no significant improvement . Of the 26 patients receiving dipyridamole , 21 ( 81 per cent ) showed an overall satisfactory clinical response ( marked or moderate improvement ) compared to 2 ( 9 per cent ) of the 22 receiving placebo . The difference between the two treatments was statistically significant . Evaluation of objective criteria also showed the superiority of dipyridamole . The mean improvement for drug group vs. placebo group was as follows : decrease in anginal attacks , 48/24 per cent ; decrease in need for nitroglycerin , 50/18 per cent ; and increase in walking distance , 84/36 per cent . In terms of subjective evaluation of anginal pain , 69 per cent of the drug group improved compared to 18 per cent of the placebo group . Two patients had reactions while taking the drug . Transient blurred vision was noted by one patient , but it did not interfere with continuation of dipyridamole .  Nausea and insomnia in another patient ( not in the final study group ) caused cessation of therapy . No reactions were reported among the placebo patients . From the results of this controlled study it is concluded that dipyridamole , a non-nitrate coronary vasodilator , is a relatively safe and effective agent for the long-term treatment of patients with angina pectoris
This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .